US2007010676A1PendingUtilityA1

Stereospecific enrichment of heterocyclic enantiomers

58
Assignee: R T ALAMO VENTURES I LLCPriority: Oct 25, 2001Filed: Apr 27, 2006Published: Jan 11, 2007
Est. expiryOct 25, 2021(expired)· nominal 20-yr term from priority
C07B 2200/07Y02P20/582C07D 215/36
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes methods for the stereoselective synthesis of heterocyclic enantiomers. The methods of the present invention incorporate the stereo-preferred oxidation of quinolone thiomethyl intermediates by optically active camphor based oxaziridines to provide R(+) or S(−) quinolone methylsulfinyl derivatives.

Claims

exact text as granted — not AI-modified
1 . A method, comprising: 
 a) providing: i) a flosequinan racemate; ii) triphenylphosphine; and    b) reacting, in a solvent, said flosequinan racemate with said triphenylphosphine under conditions such that a racemic mixture of 7-fluoro-1-methyl-3-methylthio-4-quinolone is produced.    
   
   
       2 . The method of  claim 1 , wherein said solvent is selected from the group consisting of carbon tetrachloride and a mixture of xylene and carbon tetrabromide.  
   
   
       3 . The method of  claim 1 , further comprising: 
 c) treating said racemic mixture of 7-fluoro-1-methyl-3-methylthio-4-quinolone with (1R)-(−)-(10-camphorsulfonyl)oxaziridine under conditions such that R-(+)-flosequinan is produced in enantiomeric excess.    
   
   
       4 . A method, comprising: 
 a) providing: i) a flosequinan racemate; ii) triphenylphosphine; and    b) reacting, in a solvent, said flosequinan racemate with said triphenylphosphine under conditions such that a racemic mixture of 7-fluoro-1-methyl-3-methylthio-4-quinolone is produced.    c) treating said racemic mixture of 7-fluoro-1-methyl-3-methylthio-4-quinolone with (1S)-(+)-(10-camphorsulfonyl)oxaziridine under conditions such that S-(−)-flosequinan is produced in enantiomeric excess.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.